Pooled analysis of currently available Cardiovascular Outcome Trials (CVOTs) of glucose-lowering medications reported that dipeptidyl peptidase-4 inhibitor (DPP-4i) and GLP1-RA resulted in a neutral effect on heart failure hospitalization in patients with T2DM. Here, DPP4 is linked to heart failure.